Sanofi Lifts 2026 Outlook As Dupixent Sales Jump 34.8% To €5.7 Billion
The drugmaker now sees low-teens sales growth and mid-teens business EPS growth at constant rates, with third-quarter business EPS at €3.55.
Sanofi, the biopharma company behind the Dupixent antibody, raised its 2026 guidance on Friday after third-quarter sales reached €14,444 million, up 14.3% at constant exchange rates and 16.2% at actual rates. Business EPS, the company's adjusted per-share earnings, rose to €3.55, up 19.6% at constant rates and 22.0% at actual rates.
Higher guidance for the year
Sanofi now expects 2026 sales to grow by a low-teens percentage at constant exchange rates, and business EPS to grow by a mid-teens percentage. Currency is estimated to cut about 1% from each, using October average rates, the company said in its release.
Business operating income was €5,430 million, up 22.2% at actual rates and 19.7% at constant rates. Under standard IFRS accounting, EPS was €2.52. Free cash flow came to €3,269 million for the quarter.
For the first nine months, sales were €36,550 million and business EPS was €7.52. IFRS net income for the period was €4,979 million, down 42.2%, in a year that included a €952 million impairment on the amlitelimab intangible asset booked in the second quarter.
Dupixent above €5 billion again
Dupixent sales rose 34.8% to €5,687 million, above €5 billion in a quarter for the second time. US sales climbed 40.2% to €4,376 million, helped by strong demand and favourable gross-to-net price adjustments, the company said. Sanofi develops Dupixent with Regeneron, and higher profit sharing with the partner weighed on operating income.
Sales of newer launches grew 31.4% to €1.4 billion, led by ALTUVIIIO, Ayvakit and Rezurock.
Vaccines sales fell 6.6% to €3.2 billion on what Sanofi called anticipated phasing, with a higher share of seasonal influenza deliveries shifting to the fourth quarter. Beyfortus US sales dropped 39.3% on a lower central order from the Centers for Disease Control and Prevention.
Life after Dupixent
CEO Belén Garijo said the whole organisation is focused on managing Sanofi's post-Dupixent trajectory over the next decade. "Our priority is to protect earnings through Dupixent's loss of exclusivity," she said, adding that business development and M&A will be critical.
During the quarter Sanofi expanded its Regeneron alliance to add four long-acting antibodies, paying $1 billion upfront with up to $7 billion more in potential milestones. It also agreed with Cheplapharm to hand over 20 mature medicines in return for a 26.4% stake in the company.
Sanofi's US-listed shares closed at $43.13 on Thursday, before the release, giving a market value of $103.3 billion. The company reports fourth-quarter results on Thursday, January 28, 2027.
Sanofi will report fourth-quarter 2026 results on Thursday, January 28, 2027.
Sources
- Form 6-K — Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance — SEC EDGAR
- Sanofi Q3 earnings blow past expectations on Dupixent strength; hikes FY guidance — Yahoo Finance
- Sanofi lifts profit outlook on strong Dupixent sales (SNY:NASDAQ) | Seeking Alpha — seekingalpha.com
- Press Release: Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded | Nasdaq — nasdaq.com
- Press Release: Q3 2026: double-digit growth in sales and — globenewswire.com
- Press Release: Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded – Company Announcement - FT.com — Financial Times